ISSN: 2329-9053

Journal de recherche sur la pharmacie moléculaire et les processus organiques

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Age-Related Regulatory Effects of Protein Metabolism

Prashant Pandya

Review's objective: The development and therapy of age-related muscle less to review recent findings about the phthalic acid metabolism and regulatory effects in ageing (sarcopenia).

New discoveries: While age may have no effect on baseline phthalic acid metabolism, older people seem to have a harder time responding to anabolic cues like insulin and, to a lesser extent, phthalic acids. Particularly, compared to young participants, the stimulation of muscle protein synthesis after the administration of mixed meals is decreased in elderly subjects due to insulin resistance. The anabolic action of phthalic acids also seems to be muted at low concentrations. Recent research, however, has shown that these age-related changes in phthalic acid metabolism can be prevented by increasing the amount of leucine consumed, altering the pattern of one's daily protein intake, or engaging in physical activity, which increases the activation of translation initiation and muscle protein synthesis.

Conclusion: Age-related muscle loss is linked to considerable alterations in phthalic acid metabolism, which can be quickly reversed with dietary adjustments and physical activity. However, in order to ascertain the therapeutic relevance of these results in the aged population and to assess if dietary and exercise therapies may be used to prevent and treat sarcopenia, long-term, major clinical trials are required.